

**Comparison of the guidelines taking into account size and extent of the tumour (T)**

Localized prostate cancer				
<a href="#">S3-Guideline (Germany)</a>		<b>Low risk</b> PSA ≤ 10 ng/ml <b>AND</b> Gleason-Score 6 <b>AND</b> cT1c-2a	<b>Intermediate risk</b> PSA > 10 ng/ml - 20 ng/ml <b>OR</b> Gleason-Score 7 <b>OR</b> cT2b	<b>High risk</b> PSA > 20 ng/ml <b>OR</b> Gleason-Score ≥ 8 <b>OR</b> cT2c
<a href="#">EAU (Europe)</a>		<b>Low risk</b> PSA < 10 ng/ml <b>AND</b> Gleason-Score < 7 (ISUP grade 1) <b>AND</b> cT1-2a	<b>Intermediate risk</b> PSA 10 ng/ml - 20 ng/ml <b>OR</b> Gleason-Score 7 (ISUP grade 2/3) <b>OR</b> cT2b	<b>High risk</b> PSA > 20 ng/ml <b>OR</b> Gleason-Score > 7 (ISUP grade 4/5) <b>OR</b> cT2c
<a href="#">NCCN (USA)</a>	<b>Very low risk</b> PSA < 10 ng/ml <b>AND</b> cT1c <b>AND</b> Grade Group 1 <b>AND</b> Fewer than 3 prostate biopsy fragments positive, ≤50% cancer in each fragment <b>AND</b> PSA density <0,15 ng/mL/g	<b>Low risk</b> PSA < 10 ng/ml <b>AND</b> cT1 - 2a <b>AND</b> Grade Group 1	<b>Favorable Intermediate risk</b> PSA 10 ng/ml - 20 ng/ml cT2b-2c Grade Group 2 or 3 1 IRF <b>AND</b> Grade Group 1 or 2 <b>AND</b> < 50% biopsy cores positive	<b>Unfavorable Intermediate risk</b> PSA 10 ng/ml - 20 ng/ml cT2b-2c Grade Group 2 or 3 2 oder 3 IRFs <b>AND/OR</b> Grade Group 3 <b>AND/OR</b> ≥ 50% biopsy cores positive

Prostate Seed Brachytherapy
Monotherapy (BT)
Combined-modality radiation therapy (CRT)